Phase II study of 90Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma

Izidore S. Lossos, Jesus C. Fabregas, Tulay Koru-Sengul, Feng Miao, Deborah Goodman, Aldo N. Serafini, Peter J. Hosein, Alexandra Stefanovic, Joseph D. Rosenblatt, James E. Hoffman

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


The best upfront therapy for patients with non-gastric extranodal marginal zone lymphomas (MZLs) is not defined. We assessed the safety and efficacy of radioimmunotherapy with 90yttrium (90Y) ibritumomab tiuxetan as upfront therapy in MZL (NCT00453102). A total of 16 patients were enrolled, 81% with advanced-stage disease and 44% with bulky disease. The overall response rate (ORR) at 12 weeks post-therapy was 87.5% (90% confidence interval [CI]: 65.6-97.7%), including a complete response in eight (50%), complete response unconfirmed in one (6%) and partial response in five (31%) patients. With a median follow-up of 65.6 months (range 4.0-96.5), the median progression-free survival (PFS) was 47.6 months (range 4.0-93.3) and median overall survival (OS) was not reached. The 5-year PFS was 40% (90% CI: 19.9-59.5%) and 5-year OS was 71.8% (90% CI: 46.8-86.5%). Overall, 90Y ibritumomab tiuxetan was well tolerated and led to long-term responses and PFS rates.

Original languageEnglish (US)
Pages (from-to)1750-1755
Number of pages6
JournalLeukemia and Lymphoma
Issue number6
StatePublished - Jun 1 2015


  • Marginal zone lymphoma
  • Radioimmunotherapy
  • Y ibritumomab tiuxetan

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Phase II study of <sup>90</sup>Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma'. Together they form a unique fingerprint.

Cite this